كليكسان

국가: 이스라엘

언어: 아랍어

출처: Ministry of Health

지금 구매하세요

환자 정보 전단 환자 정보 전단 (PIL)
29-11-2022

유효 성분:

ENOXAPARIN SODIUM 20 MG / 0.2 ML

제공처:

SANOFI - AVENTIS ISRAEL LTD

ATC 코드:

B01AB05

약제 형태:

SOLUTION FOR INJECTION

관리 경로:

I.V, S.C

Manufactured by:

SANOFI WINTHROP INDUSTRIE, FRANCE

치료 그룹:

ENOXAPARIN

치료 징후:

Enoxaparin sodium is an anti-coagulant. At dosesof 20 mg and 40 mg it is indicated for: - Prophylactic treatment of thrombo-embolic disorders of venous origin and in particular in orthopedic surgery or in general surgery. - Prevention of thrombus formation in the extra-corporeal circulation during hemodialysis. At dosege of 40 mg the indications are: - Prophylactic treatment of deep vein thrombosis in patients who are bedridden due to an acute medial disorder: - Heart failure (HYHA class III or IV) - Acute respiratory failure - Episode of acute infection or acute rheumatic disorder combined with at least one other venous thromboembolic risk factor. At high doses of 60, 80 ,100 mg Clexan is indicated for: -Treatment of deep vein thrombosis (DVT). - Treatment of unstable angina and non-Q-wave myocardial infaction administered concurrently with aspirin. - Treatment of pulmonary embolism.Treatment of acute ST- segment elevation myocardial infarction, in combination with a thrombolytic agent in patients eligible o

승인 날짜:

2010-02-01

다른 언어로 된 문서

환자 정보 전단 환자 정보 전단 영어 29-11-2022
제품 특성 요약 제품 특성 요약 영어 29-11-2022
공공 평가 보고서 공공 평가 보고서 영어 17-08-2016
환자 정보 전단 환자 정보 전단 히브리어 29-11-2022

이 제품과 관련된 검색 알림

문서 기록보기